Summary of studies, including rituximab and intensive induction therapy
| . | Nordic12 . | MDACC11 . | HOVON13 . | GOELAMS14 . | GELA . |
|---|---|---|---|---|---|
| No. of patients | 160 | 97 | 62 | 17 | 60 |
| CR/CRu rate, % | 60 | 87 | 64 | 92 | 78 |
| ORR rate, % | 96 | 97 | 70 | 96 | 82 |
| PFS/TTF/EFS | 4-year PFS: 73% | Median TTF: 5.9 y | 4-year FFS: 46% | 3-year EFS: 75% | 5-year EFS: 64% |
| OS | 4-year: 81% | Projected 10-year: 64% | 4-year: 79% | 3-year: 76% | 5-year: 75% |
| . | Nordic12 . | MDACC11 . | HOVON13 . | GOELAMS14 . | GELA . |
|---|---|---|---|---|---|
| No. of patients | 160 | 97 | 62 | 17 | 60 |
| CR/CRu rate, % | 60 | 87 | 64 | 92 | 78 |
| ORR rate, % | 96 | 97 | 70 | 96 | 82 |
| PFS/TTF/EFS | 4-year PFS: 73% | Median TTF: 5.9 y | 4-year FFS: 46% | 3-year EFS: 75% | 5-year EFS: 64% |
| OS | 4-year: 81% | Projected 10-year: 64% | 4-year: 79% | 3-year: 76% | 5-year: 75% |